abstract: Preimplantation genetic diagnosis (PGD) for structural chromosome abnormalities traditionally uses fluorescence in situ hybridization (FISH) techniques. Although relatively straight forward, FISH is technically demanding with several process problems which include cell loss, cell overlap, variable cell fixation and hybridization as well as sample mosaicism. Increasingly, alternative techniques for chromosome analysis in embryos are being investigated in an attempt to improve on current test outcomes. Here, we report on the first routine application of a polymerase chain reaction (PCR)-based protocol for translocation analysis utilizing multiplexed short tandem repeat (STR) markers located on both segments of the translocated chromosomes. Resulting STR profiles permit the analysis of qualitative dosage of each chromosomal segment to identify translocation malsegregants from the balanced/normal chromosome complements. A total of 29 patients have undergone clinical PGD testing of 78 embryos using this method. The proportion of alternate segregations (i.e. balanced carrier and non-carriers) detected for reciprocal and Robertsonian translocation carriers was 33% and 77%, respectively. Fetal heart pregnancy rates per embryo transferred was 46% for reciprocal carriers and 40% for Robertsonian carriers (mean number of embryos transferred was 1.0). This novel approach can be applied easily within any existing PGD PCR laboratory and allows for a significant improvement in the identification of segregation types when compared with the standard FISH protocol using combinations of distal and proximal probes. This approach increases test robustness and reliability with improved interpretation of segregation outcomes, decreased analysis time and also enables the straight forward combining of structural chromosome analysis with monogenic testing.
Introduction
Chromosomal rearrangements are a relatively common genetic variation found in 1 in 380 newborns. Reciprocal translocations occur in 1 in 625 live births and usually result from the exchange of two terminal segments from different chromosomes. Robertsonian translocations occur in 1 in 900 live births and involve exchanges occurring close to the centromeres of two acrocentric chromosomes (Van Dyke et al., 1983) .
Balanced translocations are 10 times more common in IVF patients and are reported in over 3% of people experiencing repeated implantation failure following IVF treatment (Stern et al., 1999) . Meiosis-associated malsegregation of translocated chromosomes during spermatogenesis or oocyte maturation may be responsible for the subfertility and/or recurrent miscarriages often reported in couples where one partner carries a balanced translocation.
For reciprocal translocations, the quadrivalent structure which is formed at meiosis I through matching of homologous segments undergoes one of three modes of segregation: 2:2 alternate (resulting in a normal or balanced chromosome complement), adjacent 1 and 2 (resulting in segmental monosomies and trisomies), 3:1 (resulting in tertiary trisomy and monosomy and interchange trisomy and monosomy) and 4:0 (leading to double trisomy or double monosomy). The trivalent structure formed in Robertsonian translocations results in alternate, 2:1 (adjacent 1 and 2) and 3:0 segregation patterns. In both cases, it is only the alternate segregations that result in chromosomally normal or balanced embryos.
The reproductive risks for translocation patients can be estimated by studying the specific chromosomes involved and their breakpoint locations (Gardener and Sutherland, 2004; Jalbert et al., 1988; StengelRutkowski et al., 1988) . In this way, each family presents with a unique and individual risk for their specific translocation and resulting reproductive challenges, which may include increased miscarriage rates and abnormal live births. Both outcomes can be minimized through the use of preimplantation genetic diagnosis (PGD) to differentiate balanced from unbalanced karyotypes in embryos.
PGD is typically performed at the cleavage stage of embryo development with the removal of a blastomere(s) from a 6-8-cell embryo. Polar body biopsy is also employed but is limited to disorders of maternal origin as this test is conducted prior to fertilization. More recently, the introduction of trophectoderm biopsy into routine PGD application has been reported. Trophectoderm biopsy offers some technical advantages over blastomere analysis as well as the additional embryo selection criteria resulting in only the most viable embryos being tested at the blastocyst stage of development. Blastocyst stage biopsy allows for a greater number of cells to be sampled, which improves DNA amplification-based test reliability, and improved implantation rates are observed following embryo biopsy and transfer compared with cleavage stage biopsies (McArthur et al., 2005 (McArthur et al., , 2008 .
Fluorescence in situ hybridization (FISH) testing in translocation patients can be done with breakpoint spanning probes or centromeric/subtelomeric probe combinations. The commercial availability of quality-controlled centromeric, locus specific and subtelomere probes allows for a simplified approach that laboratories can apply routinely. Breakpoint probes require access to extensive probe libraries and then require screening to identify the appropriate clone(s).
The technical constraints of FISH procedures for the detection of aneuploidy in embryos are well-documented (Munne, 2002; Velilla et al., 2002; De Ugarte et al., 2008) and include cell loss during the fixation process, signal overlap, signal splitting, variable cell fixation, which results in residual cytoplasm affecting probe attachment and resulting in poor hybridization, all of which can confuse signal interpretation. The use of blastocyst stage biopsy to improve PGD outcomes involves analysing more than one cell. Multiple cell analysis may increase the possibility of any of these technical issues causing interpretation difficulties. Error rates for translocation FISH protocols, tested on blastomeres from research embryos, have been reported in some studies to range from 0% to 10% with an average error rate of 6% (Munne et al., 2000) . In addition, the mosaicism reported as commonly occurring in rapidly dividing embryos could lead to misinterpretation of statusespecially for diploid/aneuploid mosaics (Vanneste et al., 2009) .
The application of polymerase chain reaction (PCR) protocols for the detection of single-gene disorders has been used in PGD extensively over the last 20 years. The use of fluorescence PCR has allowed the identification of allele drop out (ADO) and recombination events, positive embryo identification, the detection of extraneous DNA contamination and the ability to apply general genetic linkage principles to a wider group of single-gene patients to give a more reliable and robust embryo test. There have not, however, been any reports on the use of PCR and short tandem repeat (STR) profiling for identification of embryo's chromosome status for translocation couples.
Materials and Methods

Subjects and clinical indications
The average age of women who presented for translocation testing at our clinic during the period of PCR testing was 33.1 years (range 28.0 -39.3) for reciprocal patients and 33.3 years (range 30.7-39.0) for Robertsonian patients. Twenty-two cycles were initiated by patients who carried reciprocal translocations and seven cycles were initiated by patients who carried Robertsonian translocations.
Test design and validation
The design and basis of the test is straightforward. Two markers are chosen on each translocated chromosome segment, and generally a distance of two sub-bands (550 bphs) (ISCN, 2009 ) from the reported breakpoints was used as a minimum for STR location. This accounts for the well understood limitation of cytogenetic analysis to be able to more accurately assign the exact position of the breakpoints (see Fig. 1 for an example of the STR selection strategy).
An example of an STR profile for a translocation couple is given in Table I (section a). The predictable combinations of the mono-, di-and tri-allelic events at STR markers generated through the presence of balanced/normal (di-allelic for all STRs) and unbalanced (combinations of mono and tri allelic STRs) is given in Table I (section b).
After STR amplification and analysis, the embryo's chromosome interpretation is related to the number of peaks present at any marker, i.e. the number of alleles at each marker indicates the number of chromosomal segments present. For example, the loss of chromosome material due to an abnormal segregation from the carrier parent, results in an allele inherited only from the other parent (a mono-allelic state is present in the embryo). When there is an extra chromosomal segment from the carrier parent, it will be seen as the presence of a tri-allelic state for STR markers within the segment. The segregation prediction for each unbalanced chromosome state is made using standard cytogenetic segregation tables. Although the specific allele for any marker will vary for any of the segregants, the composite pattern will follow the same simple rules and show combinations of mono-, di-and tri-allelic states according to the segregant type.
Extensive screening of chromosome specific STRs is involved to find markers where the carrier is heterozygous and where alleles are not shared with the partner. These can be either existing STRs previously validated in the laboratory for use in PGD for single-gene disorders or new highly polymorphic markers [i.e. those with high heterozygosities (0.70 or greater) and large numbers of alleles] found with the aid of genetic databases (UCSC and GeneLoc). The use of tetra-, penta-or hexa-nucleotide markers may simplify interpretation of adjoining alleles which may be difficult to interpret if large degrees of STR stutter are present.
To make the test efficient, chosen markers are multiplexed to obtain results within primary and/or secondary amplifications. Typically, primer pairs are combined in the primary mix at concentrations ranging from 0.03 to 0.3 mM depending on amplification balances between the markers. Markers that are not able to be analysed within the primary amplification are reamplified using diluted primary amplification PCR product in a secondary amplification (either singly or in multiplex).
Optimized multiplex sets were validated on the patient's DNA samples as well as checked for amplification efficiencies on a series of cumulus/ coronal cells (1-5 cells per reaction). The low copy number reactions permitted the determination of ADO rates (ADO is defined as the failure of one of two expected alleles at a heterozygous locus to amplify to a detectable level and should be ,10%; PGDIS Guidelines for Good Practice in PGD, 2007) . In addition, a series of blank reactions were used to test for background/reagent DNA contamination.
ADO rates from validation samples were shown to range from 0% to 2.4% (average across all mixes tested was 0.7%). There were no cases of complete amplification failure.
Building the customized primer sets is straightforward. Typically the initial STR screening process, with an adequate STR library available, takes 2 days. Marker multiplexing involves trialling of combinations of primers to achieve a balance of PCR product within the multiplex reaction and typically takes 5 -8 days. Final validation of amplification mixes is then performed independently by two scientists. The possibility of utilizing existing STR resources available from monogene PGD or other translocation workups minimizes the cost of developing any new tests.
Two of the couples presenting with a balanced translocation also required a single-gene disorder (cystic fibrosis) to be analysed. This PCR approach for translocation testing also allowed for the inclusion of CFTR-linked markers and mutation detection for the CFTR gene region of interest.
Initial evaluation of the PCR approach was carried out through the use of prior FISH-analysed abnormal embryos or clinically non-usable embryos donated by patients who participated in the validation phase. Twenty-five embryos were analysed by the PCR assay, and all results enabled assignment of an identifiable segregation type. Ten of these embryos were able to be assessed using both test methods (Table II) .
Embryo culture and biopsy
Embryos were cultured to blastocyst stage in sequential media as reported previously (de Boer et al., 2004) . On Day 3 of development, viable embryos underwent an assisted hatching procedure by making a small opening in the zona pellucida with the aid of a Zilos TK laser (Hamilton Thorne Biosciences, Beverly, MA, USA).
Embryos were assessed early in the morning of Day 5 for the presence of expanding trophectoderm which was suitably herniating from the zona breaching. Those with sufficient trophectoderm formation underwent a biopsy procedure as reported previously (McArthur et al., 2004) embryos requiring further development before biopsy were cultured for a further 8 -24 h before reassessment was carried out. In this way, embryos were able to be progressively tested as they became suitable for biopsy.
Polymerase chain reaction
Biopsied trophectoderm cells were washed in buffer and then transferred to 0.2 ml PCR tubes. DNA was extracted with 2 ml alkaline lysis buffer (0.2 mM potassium hydroxide, 50 mM dithiothreitol) at 658C for 10 min. The alkaline lysis buffer was neutralized by the addition of 2 ml of neutralization buffer (900 mM Tris -HCl, pH 8.3, 200 mM HCL). The remaining reaction components were then added as a master mix. Blanks and DNA controls were also amplified under the same conditions. Final concentrations of PCR reagents were as follows, 0.2 mM dNTPs, 1.5 mM MgCl 2 , 2.5 U of Fast-Start Taq (Roche) and primer concentrations as determined previously (0.03-0.3 mM). Samples were amplified using the following primary PCR amplification parameters: 958C for 7 min (948C for 30 s, 608C for 1 min 30 s) for 43 cycles for low copy number samples or 33 cycles for DNA samples followed by 728C for 10 min (2.5 h protocol). Secondary amplifications, where needed, were conducted in 15 ml reaction volumes, using a high fidelity DNA polymerase (Phusion, Finnzymes) and primer concentrations typically 0.26 mM, using the following PCR amplification parameters: 988C for 10 s (988C for 5 s, 608C for 10 s, 728C for 15 s) for 25 cycles followed by a final step at 728C for 10 s (40 min protocol).
Primer sequences used for the 46,XX,t(9;19)(q12;p12) case given in Table I are listed in Supplementary Table SI. Diluted PCR products were subjected to capillary electrophoresis on an ABI 3100 or 3130 Genetic Analyser (Applied Biosystems). Typical electrophoresis run times are 40 min per injection (16 samples). Resulting electropherogram data were analysed using either Genescan v3.7 or Genemapper v3.2 analysis software (Applied Biosystems). See Fig. 2 for an example of an electropherogram output of STR profiles.
Results
For 78 blastocysts, biopsied conclusive results were obtained in 77 embryo analyses giving an amplification efficiency of 99%. This figure   Figure 2 Peak electropherogram data from primary amplification STR analysis in a PGD cycle from a reciprocal translocation patient (46,XX,t(2;12)(q37.2;q13.1). This test consisted of five STRs, D2S352 (p23.1), D2S2241 (q23.3), D12S811 (q24.13), D12S79 (q24.2) and D12S1034 (p12.1) which provided results in the first amplification (above) and a further three markers, D2S388 (p11.2), D12S1330 (q24.1) and D12S391 (p13.2), providing information upon secondary amplification. Embryo 1 above shows an allele pattern consistent with an adjacent 1 segregation mode resulting in a partial monosomy for the region 12q13.1 qter (three markers indicating absence of maternal inheritance). Embryo 2 above shows an allele pattern consistent with a tertiary trisomy segregation mode resulting in combined partial trisomy for the region 2pter q37.2 and 12q12 qter (total of six markers indicating trisomy).
compares to a 93% rate of conclusive FISH test results reported in a series of translocation patients studied from both cleavage and blastocyst stage biopsies at our PGD clinic (McArthur et al., 2008) . For the total 77 embryos which produced positive amplification products, an estimated clinical ADO rate of 1.8% was observed. No contamination events were detected. All embryos with a positive amplification met the minimum criteria for ascertainment of genetic status (i.e. results were obtained for all segments covered by the translocation breakpoints) and no partial profiles leading to inconclusive results were generated.
Patients with Robertsonian translocations produced a larger number of normal/balanced embryos (and hence gametes) than those with reciprocal translocations, 76% versus 33% (Table III) . These results correlate well with reported studies in gametes from translocation patients which showed that the majority of spermatozoa of carriers of Robertsonian translocations are derived from an alternative segregation and that carriers of reciprocal translocations show predominantly abnormal segregations (Van Hummelen P et al., 1997; Escudero et al., 2000; Cora et al., 2002; Anahory et al., 2005; Nishikawa et al., 2007) Studies into the incidence of diploid-aneuploid mosaicism in otherwise normal embryos cultured to the blastocyst stage indicate that it is present in a considerable proportion (17.6%) of IVF produced blastocysts (Bielanska et al., 2005) . It was found to be present in blastocysts of morphology compatible with implantation and the proportion of aneuploid cells to be a small percentage of the overall population. Any mosaicism in the trophectoderm sample has the potential to complicate the interpretation of the translocation status when analysing individual cells using FISH protocols; the presence of a single abnormal cell signal pattern within a group of cells being analysed could result in a false-positive assignment of genetic status. Our own data, based on blastocyst stage culture, biopsy and transfer, indicates that the presence of diploid -aneuploid mosaicism may be a contributing factor (along with probe error rates) towards some of the translocation FISH analyses which resulted in abnormal signal patterns of uninterpretable translocation segregation types and could account for the differences in abnormality rates between the two methods of FISH and PCR [FISH unfavourable outcomes reported at a total of 76% (McArthur et al., 2008) and PCR total of 58% (Table III) ].
Data from other experienced PGD centres applying FISH protocols to translocation testing also report similar abnormality rates in embryos tested, with one centre reporting an average of 75% abnormal embryos regardless of type of translocation (Munne et al., 2000) and ESHRE PGD consortium data collection IX reporting the rate of embryos with unsuitable results at 76% (Goossens et al., 2009) .
In order to reconfirm the results obtained from the multiplex PCR approach, rebiopsy of seven embryos identified as unbalanced by PCR was done. The samples from these embryos were assessed for chromosomal losses and gains by using comparative genomic hybridization (CGH). In six embryos, PCR results with segmental gains and losses were confirmed by the CGH results (results not shown here). All embryos confirmed the original PCR segregation assignments. One embryo did not give a DNA amplification product suitable for CGH analysis.
Discussion
Carriers of translocations represent a unique challenge in PGD. They generally are a fertile subgroup of IVF patients with a higher than usual risk of chromosomal abnormality in their gametes and consequently their embryos. Several different FISH-PGD approaches have been historically applied to this group of patients in order to reduce the spontaneous miscarriage rate and avoid abnormal live births. Although relatively successful, FISH protocols encounter multiple variable factors that can affect the accuracy of the interpretation. These factors include technical problems of signal and cell overlap, suboptimal hybridization resulting from variable cell fixation and interpretation difficulties from biological variables, e.g. through the presence of mosaicism and probe error, which together can result in varying error rates dependent on the expertise of the laboratory applying the testing.
It is proposed that there are significant advantages of the molecular approach to translocation testing outlined in this paper when compared with FISH. First, the removal of a requirement for the more technically demanding cell fixation step, compared with the simple transfer of tissue into PCR tubes, can decrease the percentage of analyses where no result is obtained or cell overlap makes interpreting the signals difficult. Second, reading individual cell signal patterns which are subject to cell-to-cell signal mosaicism leading to interpretation difficulties and an inability to assign a simple segregation mode is avoided.
With the use of a DNA amplification-based approach as outlined here, the interpretation problems associated with low-level somatic mosaicism, common in embryos (Vanneste et al., 2009) , are partially overcome since the tissue sample (typically consisting of 3-5 cells) is analysed as a whole and the averaging effect allows for interpretation of the constitutional chromosomes under investigation. The presence of abnormal cells from meiotic non-disjunction of the chromosomes being analysed are able to be detected using this approach since a tri-allelic state would still be expected to be observed in as little as one in five cells.
Third, in Robertsonian translocation cases where there is the potential for uniparental disomy (UPD) phenotypes, especially involving chromosomes 14 and 15 (Engel, 1980; Kotzot and Utermann, 2005; Shaffer, 2006) , risks can be reduced since the results from the DNA analysis allow for the confirmation of biparental inheritance. FISH analysis would fail to identify UPD since two non-differentiating signal patterns would still be present. Additionally, more embryos per couple may be available for testing since 0PN and 1PN embryos, often considered unsuitable for testing via FISH translocation protocols, can now be included since the DNA profiles obtained will confirm whether they were derived from normal fertilization events.
Finally, the amount of time required until final results are interpreted is greatly reduced when compared with the hybridization and signal interpretation usually needed when analysing by FISH (typically 6-16 hrs for FISH compared with 4-5 h for this PCR approach).
The longer culture of embryos to the blastocyst stage allows for the better developing embryos to be selected for testing as blastulation has proven to be an effective embryo selection process differentiating those embryos with potentially higher implantation potential (McArthur et al., 2004) . In addition, amplification efficiency achieved through using multiple cells available from the blastocyst stage are likely to be higher than those from single-cell biopsies (McArthur et al., 2004) and ADO is reduced. In addition, it is possible that biopsy at the blastocyst stage is less detrimental to embryo development and implantation. McArthur et al. (2004) reported improved implantation rates for blastocyst biopsy and transfer compared with Day 3 biopsy with subsequent blastocyst transfer.
With the aid of standard segregation models, expected STR allele patterns for each marker on each of the chromosome segments can be predicted. ADO and recombination meant a minimum of two markers on each chromosome segment are suggested to be used for interpretation so that a result at each segment is obtained. The total profile is interpreted as balanced/normal or as a set of losses and/or gains.
The use of multiple markers in each chromosomal segment being tracked reduces the risk of misinterpretation of apparent mono-allelic states generated through ADO. In the same manner, the risk that any tri-allelic states not observed because of ADO or recombination events masking the presence of extra chromosome segments is reduced. The predictable combination of these mono-, di-and tri-allelic events act as a confirmation in each segregant outcome and allows for specific meiosis I segregant modes to be identified and distinguished from each other (Table I , section b). In addition, the relatively large distances between marker sets also give the possibility of detecting meiosis II segregation failures.
Amplification results from all segments must be analysed to permit a confident assignment of genetic status. The test design means that a minimum of two markers (typically four) across any segregation is observed for any abnormal segregation. Information from the entire profile must be taken into consideration when assigning the genetic status. The presences of mono-or tri-allelic loci combinations are then simply interpretable as an unbalanced/abnormal segregant.
The combination of patterns predicted from markers in each of the chromosomal segments means that false-positive interpretations are virtually eliminated. In the same way, it is the combination of patterns that reduces the likelihood of a false negative since multiple ADO or recombination events would need to occur to make a profile that should contain multiple tri-allelic states appear di-allelic and hence balanced/normal. The existence of mono-allelic marker patterns in the same segregation outcome prediction would also act as an affirmation of the test since these uniparental patterns will not be affected by recombination events.
It is conceivable that recombination events can combine with meiosis II malsegregation and produce situations where information at some of the STR markers being used with this approach will not be abnormal (false-negative results). This situation represents the highest risk of error but the use of multiple markers across all chromosome segments involved minimizes this possibility.
A potential limitation for routine application of this approach is that DNA amplification protocols require a minimum level of molecular biology experience as well as a laboratory environment where DNA contamination and PCR cross-contamination are avoided. This molecular approach however may be quite appropriate in PGD laboratories already performing single-gene PGD testing. The skill sets already existing in established PGD molecular laboratories would allow for an easy implementation of this translocation PCR testing process. Beyond the already existing techniques of multiplex PCR, a simple expansion on the basic understanding of the interpretation of the genetics of meiotic segregation is all that is required.
The initial set-up costs as well as the expertise levels required may mean that FISH-based protocols are still appropriate for some PGD laboratories. There may also be some limitations to using this molecular approach for some complex rearrangements and large inversions which are likely to still be most conveniently analysed using an FISHbased testing approach.
Newer techniques, such as array CGH, can give even further comprehensive chromosomal analysis but would still require validation for the chromosome regions involved as well as an acquisition and implementation of new technologies into existing practice (Wells and Delhanty 1996; Fragouli et al., 2006; Wilton et al., 2003) . Although these newer technologies are still in their development phase and not widely available at the clinical level, this translocation PCR approach provides an appealing improvement on current FISH outcomes.
The use of this molecular approach to chromosome analysis resulted in a clinical pregnancy rate achieved using this method of 44% per transfer cycle and 29% per oocyte retrieval (OR) ( Table IV) (all now post 20 weeks gestation), which is readily comparable to our previous FISHbased results (not reported here) and the most recently reported ESHRE PGD Consortium data collection IX for translocation patients (28.5% and 16.9%, respectively) (Goossens et al., 2009 ).
An extension of this approach, which will enable the accurate determination of balanced and normal chromosome complements through linkage association to translocation breakpoints, is currently under development. 
